Why the study?
Cystatin C is involved in the pathophysiological processes of chronic inflammatory diseases, but its effects on these conditions and its therapeutic prospects warranted review.
Key points are not available for this paper at this time.
Design
Review
Cystatin C should not yet alter clinical practice; leaves open its biomarker and therapeutic potential in cardiovascular inflammation.
Cystatin C (Cys-C) is a protease inhibitor that can be produced by nuclear cells in the human body. Its principal function is to inhibit the activity of various cysteine proteases in vivo. In addition, Cys-C also plays an essential role in regulating antigen presentation, extracellular matrix degradation, and the balance of protein production and decomposition in living cells. Cys-C is involved in the pathophysiological processes of chronic inflammatory diseases, including cardiovascular, cerebrovascular, and respiratory diseases. This article reviews the effects of Cys-C on chronic inflammatory diseases and its therapeutic prospects.
No takes yet. Share an insight, caveat, or question.
Yixing Huang (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: